CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Premier Inc.

Denise Juliano, Group Vice President of Life Sciences

The Imperative Need for BI and CDS Tech in Healthace

Denise Juliano

Denise Juliano

Over my career in healthcare, I’ve seen dramatic changes across many areas. Today’s common practices were novel at one time, such as using antibiotics to treat infections. Similarly, what we view as barbaric today, was once cutting edge. The next frontier in healthcare is having smart business intelligence and clinical decision support (CDS) technologies that aid clinicians in making the best choices for their patients at the point of care – be it a hospital room, doctor’s office, clinic or other setting.


As life sciences companies create innovative therapies, it is incumbent upon them to demonstrate their value. It takes about 17 years for a medical advancement to become standard practice, and only about half of all recommended, evidence-based standards of care are provided to patients. This is largely due to the vast amount of information and research that clinicians must retain. In fact, a new peer-reviewed journal article, scientific study or research publication is released every 26 seconds. If a physician read and retained two of these articles every night, at the end of a year, they would still be about 1,000 years behind the current evidence.


90 percent of every U.S. healthcare dollar results from a physician decision that is entered into the electronic health record (EHR), however, more than 20 percent of these services are typically unnecessary and wasteful. It is estimated that in 2011, between $158 billion and $226 billion dollars was attributed to overtreatment.


Additionally, medical errors – either mistakes of omission or commission – remain the third leading cause of death for patients in the United States.


Given the complex interplay between patients, health systems, research and other factors that influence every decision made, clinicians need better ways to access the newest evidence and medical advancements available at the point of care.


It is critical that they have validated, relevant and easy-to-access clinical guidelines to quickly inform their behavior so that they can deliver the right treatment at the right time. Technologies that achieve this are on the market today but haven’t been widely adopted yet, even though everyone understands that the cloud has far more cognitive capacity than the individual.


SaaS-based applications are becoming increasingly the way organizations can quickly and easily leverage new applications


Integrated CDS programs – like Stanson Health, which Premier Inc. recently acquired – can help close the evidence gap and allow more appropriate decisions to be made that can significantly reduce costs, while still providing proper patient care. In many cases, even better, faster care.


With today’s EHR, guidelines for order sets and care plans from hundreds of sources can be electronically integrated into the clinical workflow and provide recommendations at the point of care. Next generation CDS solutions have dynamic, cloud-based capabilities with embedded alerts that give providers the opportunity to generate a greater return on their EHR investment. However, they must continuously leverage sophisticated logic and validation through testing evidence-based guidelines around the use of therapies in live environments to ensure they are achieving value for both the clinician and the patient.


CDS solutions that enable prompt, meaningful and actionable decisions are the next innovation that CIOs and life sciences companies should be paying attention to. As they evolve, CDS solutions are quickly becoming a clinician’s best friend, helping them make fast, evidence-based decisions so they can focus on providing the best care to their patients.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/leadership-perspective/the-imperative-need-for-bi-and-cds-tech-in-healthace-nwid-188.html